IL17A and myeloid sarcoma: Given that both IFNγ-producing Th1 and IL-17A-producing Th17 are critical drivers of the immune-mediated demyelination in MS, this finding suggests that KOR agonist treatment not only enhances remyelination but also reduces the myelin-damaging immune response.